Search Results
Your search for it matches 15453 pages
Showing 9001 - 9050AACR 2017: Adding the IDO-Pathway Inhibitor Indoximod to Pembrolizumab Improved Response Rate in Melanoma
Adding the investigational immunotherapy indoximod to the immunotherapy pembrolizumab (Keytruda) increased the proportion of patients with advanced melanoma who responded to treatment compared with previously reported response rates for pembrolizumab monotherapy, according to interim results from a ...
AACR 2017: IDH-Mutant Cancers May Be More Amenable to Treatment With PARP Inhibitors Than IDH Inhibitors, According to Preclinical Findings
Tumors with mutations in the proteins isocitrate dehydrogenase-1 or -2 (IDH1/2) exhibited features similar to BRCA-mutant tumors and were more likely to respond better to PARP inhibitors than to IDH inhibitors, according to preclinical data presented by Sulkowski et al at the 2017 American...
Gut Bacteria May Enhance, or Hamper, Response to Anti–PD-1 Agents
The microbiome has become an area of intense interest for many health-related reasons. Add to this list the potential for a positive or a negative effect on responsiveness to immunotherapy. Gut microbiota that were more diverse, and that contained an abundance of a particular bacterial species,...
The Mystery of Grace
The day after I told Nell she had seven metastases to her brain, she sent me flowers. She was my patient; I was her oncologist. I had met her 1 year prior, when she was well into her cancer journey, stage IV breast cancer at diagnosis. I took over from her current oncologist, who was moving. At...
ASCO’s State of Cancer Care in America: 2017 Report Acknowledges Both the Progress Made in Oncology Care and the Challenges Ahead
Despite advances in cancer risk assessment, prevention, disease detection, drug development, and health-care delivery, which have led to unparalleled reductions in cancer incidence and mortality, access to affordable health care and increased administrative burdens placed on oncology practices...
Expert Point of View: Eloise Chapman-Davis, MD
Eloise Chapman-Davis, MD, a gynecologic oncologist at New York-Presbyterian and Weill Cornell Medicine, commented on the SOLO2 trial results for The ASCO Post. “SOLO2 is the third randomized trial to evaluate the use of maintenance therapy in a selected subgroup of ovarian cancer patients with...
Olaparib Maintenance Prolongs Progression-Free Survival in Ovarian Cancer
Maintenance therapy with the tablet formulation of olaparib (Lynparza) significantly prolonged progression-free survival in patients with platinum-sensitive relapsed ovarian cancer and mutations in BRCA1/2 in the phase III SOLO2 trial, presented at the 2017 Society of Gynecologic Oncology (SGO)...
AACR 2017: Patients With Triple-Negative Breast Cancer Who Responded to Atezolizumab Had Long-Term Survival Benefit
Among patients with metastatic triple-negative breast cancer who were treated with the anti–programmed death-ligand 1 (PD-L1) immunotherapy atezolizumab (Tecentriq), those who responded to the treatment had a longer overall survival compared with those who did not respond, according to data...
AACR 2017: Combination of Nivolumab and Ipilimumab Improved Overall Survival in Advanced Melanoma
Among patients with advanced melanoma, those who received both nivolumab (Opdivo) and ipilimumab (Yervoy) had improved overall survival compared with those who received only ipilimumab, and appeared to have more favorable survival outcomes compared with those who received nivolumab, according to...
AACR 2017: 5-Year Survival Rate for Nivolumab-Treated Advanced Lung Cancer Higher Than Historical Rate in Early-Phase Trial
Treatment with the immune checkpoint inhibitor nivolumab (Opdivo) yielded durable responses in some patients with advanced non–small cell lung cancer (NSCLC), with a 5-year survival rate of 16%, according to data from a phase I clinical trial presented by Brahmer et al at the American...
Palbociclib Receives FDA Approval and Expanded Indication for First-Line Metastatic Breast Cancer
On March 31, the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for a first-in-class cyclin-dependent kinase (CDK) 4/6 inhibitor, palbociclib (Ibrance), based on the results from the confirmatory phase III trial PALOMA-2. The FDA action converts the...
AACR 2017: Combination HER2-Targeted Therapy Effective in Heavily Pretreated HER2-Positive Colorectal Cancer
A combination of two HER2-targeted therapies, trastuzumab (Herceptin) and lapatinib (Tykerb), showed clinical benefit in patients with heavily pretreated HER2-positive metastatic colorectal cancer, according to final results from the phase II HERACLES clinical trial, presented by Siena et al at the ...
AACR 2017: Addition of TTFields to Temozolomide Treatment Improves Survival for Patients With Glioblastoma
Patients with glioblastoma who wore a medical device that delivers alternating electrical fields in addition to being treated with the chemotherapeutic temozolomide had significantly improved median overall survival compared with those treated with temozolomide only, according to final results from ...
AACR 2017: Cancer Type and Mutation Identity Influenced Response to Neratinib in a Basket Clinical Trial
In the phase II SUMMIT clinical trial, the likelihood that a patient’s cancer responded to the investigational pan-HER–targeted therapeutic neratinib was influenced by both the cancer type and the identity of the gene mutation present in the cancer, according to results presented by...
Racial and Ethnic Disparities in Gene-Expression Profiling Tests in Breast Cancer
For a proportion of patients, including women with hormone receptor–positive breast cancer, gene-expression profiling has a substantial impact on treatment decision-making by determining which patients might—or might not—respond to particular treatment options. Gene-expression...
Pediatric Oncology Patient and Parent Attitudes on Early Palliative Care Integration
Few pediatric oncology patients or their parents expressed negative attitudes toward early integration of palliative care during cancer treatment, according to a study by Levine et al reported in JAMA Oncology. Study Details The study involved completion of surveys by 129 patient-parent dyads...
First-in-Human Clinical Trial of ONC201 in Patients With Refractory Solid Tumors
A first-in-human clinical trial examining the investigational small-molecule drug ONC201 in patients with advanced solid tumors showed the oral agent to be well tolerated at the recommended phase II dose, according to Rutgers Cancer Institute of New Jersey investigators whose research also showed...
Significant Increase in Number of Women Tested for BRCA Gene, but Many High-Risk Patients Remain Unidentified
About 5% to 10% of breast cancer cases and 10% to 18% of ovarian cancer cases can be attributed to two BRCA genetic mutations. Testing for these genetic abnormalities has risen steadily over the past decade. Previously, mainly women with a history of cancer were referred for genetic testing, but as ...
Intestinal Microbiota and Relapse After Allogeneic Hematopoietic Cell Transplantation
A retrospective study has shown that the presence and abundance of a particular bacterial group in the intestinal microbiota are associated with a significantly lower risk of relapse or disease progression after allogeneic hematopoietic cell transplantation. The findings were reported by Peled et...
FDA Approves Maintenance Niraparib for Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, whose tumors have achieved complete or partial response to platinum-based chemotherapy....
New Study Finds Most Cancer Mutations Due to Random DNA-Copying Errors
Johns Hopkins Kimmel Cancer Center scientists report data from a new study providing evidence that random, unpredictable DNA copying “mistakes” account for nearly two-thirds of the mutations that cause cancer. Their research is grounded on a novel mathematic model based on DNA...
Impact of 70-Gene Signature on Adjuvant Chemotherapy Decisions in Breast Cancer
In a Dutch observational study reported in the Journal of Clinical Oncology, Kuijer et al found that use of the MammaPrint 70-gene signature (70-GS) test changed physician-intended recommendations to administer adjuvant chemotherapy in half of patients with early-stage estrogen...
Guidelines Planned on Management of Immunotherapy Side Effects: ASCO and NCCN to Collaborate on Development
Given the pace of advances in immunotherapy in recent years and physicians’ need to keep up with these developments, ASCO and the National Comprehensive Cancer Network® (NCCN®) have announced a joint collaboration to publish practical clinical guidance on the management of side effects caused by...
An Evening for Cancer Survivors and Caregivers: Bringing Together a Community of Support
On January 26, 2017—prior to the official opening of the 2nd Annual Cancer Survivorship Symposium—cancer survivors, caregivers, patient advocates, family physicians, oncology providers, and others gathered in San Diego, California, to make connections, discuss survivorship issues, and get expert...
Mammography-Detected Small Breast Cancers May Represent Overdiagnosis, With Declining Mortality Reflecting Improved Systemic Therapy
In a study using Surveillance, Epidemiology, and End Results (SEER) data reported in The New England Journal of Medicine, H. Gilbert Welch, MD, of Dartmouth Institute for Health Policy and Clinical Practice, and colleagues found that screening mammography has resulted in a substantial increase in...
SIOG 2017 Advanced Course in Treviso, Italy
The International Society of Geriatric Oncology (SIOG) has a workshop to educate young investigators in geriatric oncology research. The SIOG Advanced Course, which is held in Treviso, Italy (June 28–July 1, 2017), is our unique continuing medical education–accredited training program led by...
Anne Friedman Glauber, Cofounder of Online Pancreatic Cancer Forum, Dies at Age 63
Anne Friedman Glauber, 63, co-founder of Let’s Win, an online community for persons affected by pancreatic cancer, recently passed away at her home in New York City, after a courageous battle with the disease. Ms. Glauber’s dedication to the organization (www.letswinpc.org) helped countless...
Examining the Impact of ‘Death With Dignity’ Legislation
Despite the controversy surrounding “Death With Dignity” laws, which allow physicians to prescribe life-ending drugs to terminally ill patients, they have a long history of majority support from Americans. According to a Gallup poll taken in 2015, nearly 7 in 10 Americans (68%) agreed that...
Chief Clinical Officer’s Distinguished Chair Created at City of Hope to Honor Alexandra M. Levine, MD, MACP
A significant philanthropic gift from the Campbell family of Las Vegas, Nevada, will establish a new endowed Chair to honor City of Hope’s former Chief Medical Officer Alexandra M. Levine, MD, MACP. The recipient of the Deana and Steve Campbell Chief Clinical Officer’s Distinguished Chair, to be...
Coping With an Uncommon Cancer
In April 2014, I was so sick with uncontrollable vomiting and diarrhea and severe abdominal and chest pain that I had to be hospitalized for 5 days. As I was in my late 20s and in otherwise good health, there was no easy explanation for my symptoms. After I was released from the hospital, my...
Acupuncture for the Management of Hot Flashes
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, authors Jun J. Mao, MD, MSCE, and Jyothirmai Gubili, MS, present a case study...
Implications of SWOG S0777 and the Future of Combination Treatments for Multiple Myeloma
The treatment of multiple myeloma is becoming increasingly complicated. This is not only because of the complexity of the disease, but also because of the increasing number of effective combination treatments and continuous development of new drugs. This has resulted in an ever-increasing number ...
Suresh Vedantham, MD, FSIR, Named President of SIR
Suresh Vedantham, MD, FSIR, an interventional radiologist and Professor of Radiology and Surgery at the Mallinckrodt Institute of Radiology at Washington University in St. Louis, assumed the office of President of the Society of Interventional Radiology (SIR) on March 7, 2017, during the Society’s ...
Markedly Improved Progression-Free Survival With First-Line Ceritinib vs Platinum Chemotherapy in ALK-Rearranged NSCLC
In the phase III ASCEND-4 trial reported in The Lancet, Jean-Charles Soria, MD, of Institut Gustave Roussy, and colleagues found that ceritinib (Zykadia) improved progression-free survival vs platinum-based chemotherapy in the first-line treatment of advanced anaplastic lymphoma kinase...
SSO 2017: Preclinical Trial Shows Intratumoral Vaccination Induces Antitumor Response in Pancreatic Cancer
Building on their previous research focusing on intratumoral vaccination for the most common form of pancreatic cancer, investigators from Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School have shown that in a mouse model of early-stage resected pancreatic...
ASCO Addresses New Policies That Threaten Access to Opioids
Since the mid-2000s, medication and illicit drug abuse in the United Sates has steadily increased, creating what has now been termed an “opioid epidemic.” In response, Congress and the Bush and Obama Administrations have launched intervention and regulatory proposals to help turn the troubling...
For One Hematologist, No Disease Progressions in Follicular Lymphoma With Rituximab Maintenance
Patients with follicular lymphoma are clearly living longer without disease progression, but what clinician has had no patients progress? Michael Auerbach, MD, a hematologist/oncologist in private practice in Baltimore and Clinical Professor of Medicine at Georgetown University, may have these...
Expert Point of View: Heather L. McArthur, MD, MPH
Discussant Heather L. McArthur, MD, MPH, Medical Director of Breast Oncology at Cedars-Sinai Medical Center, Los Angeles, called the plinabulin findings “provocative,” especially considering the substantial impact on durability of response. Specifically with the addition of plinabulin to docetaxel, ...
Expert Point of View: Heather L. McArthur, MD, MPH
Study discussant Heather L. McArthur, MD, MPH, Medical Director of Breast Oncology at Cedars-Sinai Medical Center, Los Angeles, noted that human papillomavirus (HPV) vaccination has been shown to prevent HPV-related malignancies and eradicate high-grade, HPV16-positive premalignant lesions....
Expert Point of View: Shridar Ganesan, MD, PhD
Shridar Ganesan, MD, PhD, of Rutgers Cancer Institute of New Jersey, discussed the study by Cristescu et al at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium. He noted that data from many sources have shown that point mutation burden correlates with response rate to checkpoint blockade....
Expert Point of View: Joseph Greer, PhD
“These data are consistent with other studies we have conducted in advanced lung cancer, in which we similarly found that one-third of patients believed that their metastatic lung cancer was curable. These patients ostensibly already had conversations with their oncologists about their prognosis...
Aligning Patient Expectations With Treatment Goals in the Metastatic Setting
More than one-third of men with incurable metastatic prostate cancer mistakenly believe that their cancer may be curable, according to a survey of patient expectations at an academic cancer center. “This study is part of a larger survey of treatment decision-making among men with metastatic...
Developing Better Multidisciplinary Strategies
“More than any other disease, head and neck cancer requires constant interplay between a number of different specialties,” Sandeep Samant, MD, Chief, Head and Neck Surgery, Northwestern Medicine, and Chair of the Multidisciplinary Head & Neck Symposium sponsored by the Robert H. Lurie...
IASLC Endorses Tobacco Reform Report Outlining Progress Toward Ending Adult Cigarette Smoking
The International Association for the Study of Lung Cancer (IASLC) has endorsed a report released by the Core Team for Tobacco Control that outlines key action items that can be taken immediately to accelerate progress toward ending cigarette smoking in adults. Issuing their Executive Summary ...
Making the Case for Sentinel Node Biopsy in Early Cancers of the Oral Cavity
“The majority of patients with oral cavity cancers will undergo an unnecessary operation,” Sandeep Samant, MD, stated at a session on managing N0 neck cancer at the 2016 Lurie Cancer Center Multidisciplinary Head & Neck Symposium in Chicago.1 That operation is elective neck dissection, and it ...
Online Symptom-Management Curriculum May Improve Depression and Fatigue in Breast Cancer Survivors
With thousands of devices to track and manage health and wellness, eHealth tools are beginning to transform modern health care and research, demonstrating quantifiable improvements in patient outcomes. According to the results of a randomized controlled trial (Reimagine), breast cancer survivors...
Expert Point of View: Ann H. Partridge MD, MPH
Ann H. Partridge MD, MPH, Director of Adult Cancer Survivorship Program at the Dana-Farber Cancer Institute, praised the “tremendous work” of Dr. Paskett and her colleagues but referred to the findings as “disappointing to say the least.”1 “Developing interventions to prevent or treat lymphedema...
Search Continues for Effective Way to Prevent Lymphedema in Breast Cancer Survivors
There was no difference in the incidence of lymphedema at 18 months in breast cancer patients randomized to a physical therapy intervention with education materials compared with a control.1 Although poor adherence to the intervention may have been a factor, these results, described as “very...
Expert Point of View: Manish A. Shah, MD
Manish A. Shah, MD, Director of Gastrointestinal Oncology at NewYorkPresbyterian and Weill Cornell Medicine, commented that “the benefit seen in patients who regularly exercise is equal to or better than the benefit seen with some chemotherapy drugs,” although he cautioned that exercise in this...
